Something new in the field of PLA/GA bioresorbable polymers?

Vert, Michel; Schwach, Grégoire; Engel, Robert; Coudane, Jean

doi:10.1016/s0168-3659(97)00240-x

Cited by 161 publications

(94 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40,41 They are widely used for the preparation of biodegradable medical devices and of drug-sustained release microspheres or implants marketed in Europe, Japan, and the U.S. 42 Degradation of PLA or PLGA occurs by autocatalytic cleavage of the ester bonds through spontaneous hydrolysis into oligomers and D,L-lactic and glycolic acid monomers. 43 Lactate converted into pyruvate and glycolate enter the Krebs' cycle to be degraded into CO 2 and H 2 O.…”

Section: General Considerationsmentioning

confidence: 99%

“…44 Degradation rate depends on four basic parameters: hydrolysis rate constant (depending on the molecular weight, the lactic/glycolic ratio, and the morphology), amount of water absorbed, diffusion coefficient of the polymer fragments through the polymer matrix, and solubility of the degradation products in the surrounding aqueous medium. 40,41 All of these parameters are influenced by temperature, additives (including drug molecules), pH, ionic strength, buffering capacity, size and processing history, steric hindrance etc. Despite a higher water uptake the PLA or PLGA blocks of mPEG-PLA/ PLGA block copolymers have similar degradation behaviors.…”

Section: General Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

Summary: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50 -300 nm generally). They cannot freely diffuse through the bloodbrain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyanoacrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)-polylactide or poly(lactide-co-glycolide) (mPEG-PLA/ PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.

show abstract

Section: General Considerationsmentioning

confidence: 99%

Section: General Considerationsmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

show abstract

“…Until now, a large number of different polymers have been investigated for formulating biodegradable nanoparticles. Among them poly(L-lactic-acid) (PLA) and its copolymers with glycolic acid called poly(D,Llactic-co-glycolic acid) (PLGA) have gained popularity as vehicles for drug delivery systems (Uhrich et al 1999;Vert et al 1998;Park et al 1995;Jain et al 2000). cleaved by hydrolysis into natural metabolites (lactic and glycolic acids), which are eliminated from the body by the citric acid cycle.…”

Section: Introductionmentioning

confidence: 99%

Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: Part II. Effect of process variables on protein model drug encapsulation efficiency

Shubhra

Feczkó

Kardos

et al. 2013

Journal of Microencapsulation

View full text Add to dashboard Cite

This study investigates encapsulation efficiency of model drug, encapsulated by magnetic PLGA (poly D,L-lactic-co-glycolic acid) nanoparticles (NPs). This is the following part of our preceding paper, which is referred in this paper as Part I. Magnetic nanoparticles and model drug human serum albumin (HSA) loaded PLGA NPs were prepared by double emulsion solvent evaporation method. Among five important process variables, concentration of PLGA and concentration of HSA in the inner aqueous phase Encapsulation efficiency of nanoparticles ranged from 18 to 97% depending on the process conditions. Higher encapsulation efficiencies can be achieved by using low HSA and high PLGA concentrations. The optimization process, carried out by exact mathematical tools using GAMS TM /MINOS software makes it easier to find out optimum process conditions to achieve comparatively high encapsulation efficiency (e.g. 92.3%)for relatively small sized PLGA NPs (e.g. 155 nm).

show abstract

“…Generally, the degradation of PLA, PGA, or PLGA involves scission of ester bond linkages in the polymer backbone by hydrolytic attack of water molecules [12]. Thus, compared to the PCL segment only, incorporation of PLLA into the PCL segment can lead to faster chain scission because of better accessibility of water to the ester bonds of PLLA.…”

Section: Introductionmentioning

confidence: 99%